Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I jumped in Monday on the DIP and bought Jan calls 10/12.5/15 made over 100% on the first two and broke even on the 15's
Would have kept the 10's but I have losses in my account overall so taking a 2100 profit after two days was too good to pass up. I thought it'd hit 14 tomorrow but these markets MOVE quickly one way or another and options are tricky sometimes. lol So Merry Christmas
Truth be told, a drug that works on surrogate endpoints but exacerbates the actual symptoms of actual patients without improving the underlying pathology was probably never going to be a winner.
Combine that with operational incompetence on an eye-watering scale and you’ve got ICPT.
So thanks, but no thanks.
MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept's international operations, including a license to commercialize Ocaliva(R) (obeticholic acid) outside of the U.S.
"This agreement marks an important step forward for Intercept as the value it brings to our company allows us to significantly strengthen our balance sheet while providing us with greater strategic optionality during this transformational year and beyond," said Jerry Durso, President and Chief Executive Officer of Intercept. "We are committed to investing in our core focus areas in the U.S., including our PBC business, potential future activities in NASH, and our advancing and expanding pipeline. At the same time, we are confident that the strong international team will continue to build on our successful PBC business as they transition to Advanz Pharma."
Upon closing of the transaction:
-- Intercept will receive consideration in the amount of $405 million
upfront, subject to customary working capital and other adjustments. The
company will receive an additional $45 million from Advanz Pharma
contingent upon receipt of an extension of pediatric orphan exclusivity
in Europe.
-- Intercept will receive royalties on any future net sales of obeticholic
acid in NASH outside of the U.S., should Advanz Pharma pursue marketing
authorization for this indication in ex-U.S. regions.
-- Intercept will continue to be responsible for the manufacturing and
supply of obeticholic acid globally and Advanz Pharma will be responsible
for packaging, distribution and commercialization of the therapy in all
markets outside of the U.S.
-- The majority of Intercept employees outside of the U.S. will transfer to
Advanz Pharma. The remaining international employees will continue to
work for Intercept.
-- Intercept will maintain an office in the UK to manage its global supply
chain, support its quality organization, and support its global clinical
trials.
DJ Intercept Announces Advanz Pharma To Acquire Ocaliva In PBC In Markets Outside The U.S. For Up To $450MM, Including $405MM Upfront And An Additional $45MM In Contingent Payments >ICPT
$ICPT: The day it popped from $75 to $480/sh
I remember this day very very veryyyyyyyyyyyyyy well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=94008675
Now at $14.90
I'm here !
GO $ICPT
ICPT shakes off new contraindication in Ocaliva label:
https://finance.yahoo.com/news/intercept-announces-updated-ocaliva-obeticholic-203000633.html
However, my “dead money” prediction at the start of the calendar year (#msg-160656464) looks pretty safe; as I’m typing, ICPT is -31% YTD.
With a product selling not badly, it is sad the price is so awful.
ICPT is dead money. It's headed to $9, not $90.
Share price is awful ! When can it goes back to $90?
Anyone who had attended the meeting on 19 May? Any update from there?
Now it's at 20...Good move
How's your list today?
Had about a million shares purchased and or covered in the last 15 minutes of trading. Definitely on my list.
I highly doubt that. Looks like a delayed reaction to an insider buy that was filed two weeks ago but was written up on Yahoo today (https://finance.yahoo.com/news/strong-insider-buying-could-indicate-014759282.html ).
Yet another ICPT executive departs—the CFO:
https://www.globenewswire.com/news-release/2021/03/10/2190409/0/en/Intercept-Announces-Departure-of-Chief-Financial-Officer.html
Here we goooooo$$$$$
its a sort squeez play now,,im loading,,time is here n now,,tweet it out $$$$$$
ICPT’s President, U.S. Commercial &Strategic Marketing, quits:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1270073/000110465921005851/tm213669d1_8k.htm
He knows the stock is dead money.
ICPT +14% on “productive meeting with FDA” about the possibility of resubmitting the rejected NDA for Ocaliva in NASH sometime in 2021:
https://finance.yahoo.com/news/intercept-pharmaceuticals-reports-third-quarter-120000280.html
Caveat emptor.
FDA identifies new Ocaliva safety signal:
(scan up)$ICPT —This language about a new safety signal is "hidden" insofar as it was inserted in the middle of a paragraph that addresses an unrelated subject (the 2018 black-box warning in the PBC label). My view of Ocaliva continues to be as tweeted in Dec 2019: https://t.co/7WUUuQDrxT
— Roy Friedman (@DewDiligence) October 6, 2020
breaking $43 pivot,,$45 on par mhop $$$$
loading zone,,mhop $80 soon
ICPT cuts workforce 25%—170 jobs—as a result of CRL:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1270073/000110465920101204/tm2029969d1_8k.htm
ICPT receives CRL for Ocaliva NDA in NASH:
https://www.globenewswire.com/news-release/2020/06/29/2054576/0/en/Intercept-Receives-Complete-Response-Letter-from-FDA-for-Obeticholic-Acid-for-the-Treatment-of-Fibrosis-Due-to-NASH.html
Sorry. You are correct.
The PDUFA delay was announced a month ago (https://finance.yahoo.com/news/intercept-provides-regulatory-120010620.html ), although no new date was cited.
Is there something more recent?
ICPT—(-14%/PM)—FDA postpones 6/9/20 advisory panel—extends 6/26/20 PDUFA for NASH NDA to unspecified date:
https://finance.yahoo.com/news/intercept-provides-regulatory-120010620.html
Dew- Gilead CEO expresses interest in NASH and cancer assets, Dealreporter says When pressed by an analyst during its Q3 earnings call, Gilead Sciences' (GILD) CEO Daniel O'Day said the company is looking carefully in the areas of nonalcoholic steatohepatitis and in oncology, said Dealreporter, according to contacts. If Gilead "is serious about wading into NASH, which would build on its liver franchise-building expertise in HCV, Intercept Pharmaceuticals (ICPT) could be a name to watch," the deal-focused publication stated, according to contacts.
Read more at:
https://thefly.com/landingPageNews.php?id=2981475
Also:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137563501
My point, both AMRN & ICPT are key to GILD NASH success.
BB
PDUFA date for NASH NDA—>6/26/20 (instead of 3/26/20); this was expected after the FDA convened an advisory panel meeting for 4/22/20 (later than the original PDUFA date):
https://www.sec.gov/ix?doc=/Archives/edgar/data/1270073/000110465920004918/tm203659d1_8k.htm
See #msg-152827890 for related info.
ICPT—The intense focus of today’s webcast’s on discrediting liver biopsy as a NASH diagnostic was a form of lobbying directed at members of the upcoming FDA advisory panel, IMO.
Ocaliva’s sales prospects in NASH will be substantially diminished if the FDA label mandates a pre-treatment biopsy to establish a threshold fibrosis level, and this is the kind of issue where the FDA will likely seek guidance from the advisory panel.
ICPT is well capitalized and doesn’t stand to gain anything from pumping the share price. The real target audience for today’s 3.5-hour “investor” webcast was not investors!
CC slides from ICPT’s ‘NASH Commercial Day’:
http://ir.interceptpharma.com/static-files/076ed33d-3f9a-4605-a5ca-ed39c1695beb
The proper translation of “We don't know” in this context is Yes. I.e., US third-party payers will almost certainly require biopsies to reimburse for an estimated $20K/yr chronic, rest-of-life therapy for NASH—even if biopsies are not explicitly mandated in the FDA label (which remains to be seen).
ICPT spent most of today’s 3.5-hour webcast arguing that biopsies aren’t needed to treat NASH. This in itself ought to be a flag for investors.
From ICPT’s ‘NASH Commercial Day’ presentation today…
Q: “Will payers require a biopsy to prescribe Ocaliva?”
A: “We don’t know.”
$ICPT must see Intercept Pharmaceuticals Inc Nasdaq Icpt Short Squeeze
News: $ICPT Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Da...
Got this from ICPT - Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
News: $ICPT Here's Why Intercept Pharmaceuticals Stock Rose 48.9% in November
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) , a biopharmaceutical company, were up 48.9% in November, according to data from S&P Global Market Intelligence . An interim analysis of the company's big non-alcoholic steatohepatitis (NASH) trial provided the lift last month. Sin...
Read the whole news ICPT - Here's Why Intercept Pharmaceuticals Stock Rose 48.9% in November
News: $ICPT FDA Accepts Intercept's NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administra...
Read the whole news ICPT - FDA Accepts Intercept's NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
ICPT 3Q19 results:
http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-reports-third-quarter-2019-financial
ICPT raised full-year 2019 Ocaliva sales guidance (for PBC indication only) to $245-250M (from the prior range of $235-245M).
CC slides:
http://ir.interceptpharma.com/static-files/45a2334a-a7ae-4416-bb79-052be89a326e
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
625
|
Created
|
10/11/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |